The U.S. Centers for Medicare and Medicaid Services (CMS) will conduct a national coverage determination analysis of beta amyloid-directed monoclonal antibody (MoAb) treatment for Alzheimer's disease, including the new drug aducanumab.
The Alzheimer's Association applauds CMS's analysis, which would help ensure that patients who might benefit from the treatment have access. Also, the association calls on the agency to provide immediate guidance to help people navigate access to coverage as the analysis process moves forward during the next several months.
